TetraLogic Initiates Phase 1 Clinical Trial of TL32711 in Patients with Lymphoma
News Jan 11, 2010
TetraLogic Pharmaceuticals announced that the Company has completed dosing of the first cohort in a Phase 1 clinical trial of its selective SMAC mimetic, TL32711.
The Phase 1 trial is an open-label, dose-escalation study evaluating the safety and tolerability of TL32711 in adults with solid tumors or lymphoma refractory to standard therapies. The study will also assess the pharmacokinetics, pharmacodynamics and anti-tumor activity of TL32711.
“The ability of TL32711 to antagonize Inhibitor of Apoptosis Proteins in a selective manner represents a new broadly applicable approach to treat cancers that are normally resistant to therapies.”
“This is an important milestone for our Company and for cancer patients,” said John M. Gill, President and Chief Executive Officer of TetraLogic Pharmaceuticals. “The ability of TL32711 to antagonize Inhibitor of Apoptosis Proteins in a selective manner represents a new broadly applicable approach to treat cancers that are normally resistant to therapies.”
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
New Studies Demonstrate Risk Reduction Potential of Heat-Not-Burn Tobacco Products and e-CigarettesNews
Data presented at the Society of Toxicology Annual Meeting (SOT) have demonstrated the potential of two different heat-not-burn tobacco products and e-cigarettes to reduce the risk of smoking-related diseases, in comparison to continued use of conventional cigarettes.READ MORE